At Janssen Oncology EMEA, we understand that the power to change the lives of those with cancer begins with a very considered step. Forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of PurposeTM.
Despite the incredible work of the oncology community across Europe, cancer remains the second leading cause of premature death in this region.[1][2] At Janssen Oncology EMEA, we fiercely believe cancer is a challenge we can collectively overcome, and our ultimate aim is to make cancer an interceptable, even curable, or chronic disease.
We know that receiving a cancer diagnosis can be overwhelming and sparks fear. We are striving to change this, so that one day the words “you have cancer” will be less terrifying for patients to hear and less distressing for healthcare professionals to say and act upon.
Our precise purpose
Every cancer is different, each possessing unique challenges along the way.[3] But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference for patients, partners, and the entire oncology community. To do this, we consistently integrate patients' perspectives into everything we do.
Oncology in numbers
- Cancer remains the second leading cause of death worldwide. In fact, in 2020, there were an estimated 4 million new cases and 1.9 million deaths attributed to cancer in Europe.[8]
- In 2020, haematological malignancies were attributed to approximately 294,000 diagnoses and approximately 148,000 deaths in Europe.[9]
- Europe has one of the highest incidence rates of bladder cancer in the world. It is the fifth most frequently diagnosed cancer in the EU, with 151,000 new cases each year.[10] Urothelial carcinoma is the most common form of bladder cancer, making up more than 90% of all bladder cancers.[11]
- Prostate cancer is the most common cancer in men in the EU, representing approximately 22% of all male new cancer cases diagnosed,[2] but the symptoms may not present until the cancer has spread and some patients will eventually become resistant to treatment.[12][13]
- In 2020, lung cancer was the leading cause of cancer deaths in Europe, causing 384,000 deaths.[9]
Our pipeline is taking science from where it is to where it has not been before, through targeted transformation. Our areas of focus include:
Multiple myeloma
We want to improve treatment efficacy for patients with this rare, incurable blood cancer.
Read moreB-cell malignancies
There are many different types of B cell malignancies.[14] At Janssen Oncology, we’re focused on three main types.
Read moreProstate cancer
Janssen Oncology has over ten years’ experience in research in prostate cancer, the most common cancer among men in the EU. [4]
Read moreBladder cancer
Despite therapies being available, there is a high unmet need in bladder cancer due to poor outcomes. We are striving to change that.[5][6]
Read moreLung cancer
We’re concentrating on developing targeted therapies for patients with lung cancer, the leading cause of cancer death for men and women globally. [7]
Read moreRELATED STORIES
References
[1] World Health Organization Regional Office for Europe. Cancer data and statistics. Available at http://www.euro.who.int/en/health-topics/noncommunicable-diseases/cancer.... Accessed December 2020.
[2] Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356-387.
[3] Ogino S. et al. Expert Rev Mol Diagn. 2012; 12(6): 621–628. 2 TBC
[4] HEAL. Men Prostate cancer. Available at https://www.env-health.org/IMG/pdf/prostate_testical.pdf. Last accessed December 2020 European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC–White–Paper–Bladd.... Accessed December 2020.
[5] European Cancer Patient Coalition White Paper on Bladder Cancer 2016. Available at: https://ecpc.org/wp-content/uploads/2019/08/ECPC–White–Paper–Bladd.... Accessed December 2020.
[6] Kamaneh Montazeri & Joaquim Bellmunt. Erdafitinib for the treatment of metastatic bladder cancer. Expert Review of Clinical Pharmacology. 2020;13(1):1-6.
[7] Cancer.Net. Lung Cancer - Non-Small Cell: Statistics. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed December 2020.
[8] IARC. All cancer fact sheet. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sh.... Accessed June 2021.
[9] IARC. Online analysis table. Available at: https://gco.iarc.fr/today/online-analysis-table?v=2020&mode=cancer&mode_.... Accessed June 2021.
[10] European Cancer Patient Initiative. Urological cancer. Available at https://ecpc.org/news-events/bladder-cancer Accessed June 2021.
[11] Cancer.net. Bladder Cancer: Introduction. Available at: https://www.cancer.net/cancer-types/bladder-cancer/introduction. Accessed June 2021.
[12] Prostate Cancer UK. Overcoming treatment resistance. Available at: https://prostatecanceruk.org/research/research-impact/overcoming-treatme.... Last accessed: December 2022.
[13] Kirby M, et al. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180-92.
[14] WebMD. What Is B-Cell Lymphoma: Available at: https://www.webmd.com/cancer/lymphoma/what-is-b-cell-lymphoma#1. Accessed June 2021.
[15] Iyer RK, Bowles PA, Kim H, Dulgar-Tulloch A. Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges. Front Med (Lausanne). 2018;5:150.
Follow Us
CP-360796